ADMA Biologics Inc (NASDAQ:ADMA)
| 3.34 Delayed Data As of Oct 03 |  -0.20 / -5.67%Today’s Change | 2.41 Today|||52-Week Range 4.65 | -13.92% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $802.9M |
Company Description
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
Contact Information
ADMA Biologics, Inc. 465 State Route 17 South Ramsey New Jersey 07446 |
Employees
Shareholders
| Other institutional | 46.78% |
| Mutual fund holders | 28.03% |
| Individual stakeholders | 24.78% |
Top Executives
| Adam S. Grossman | President, Chief Executive Officer & Director |
| Atkinson Vernon | Operations Director |
| Brian Lenz | Chief Financial Officer & Executive Vice President |
| Kaitlin Kestenberg | Vice President-Compliance & Clinical Operations |
| Lucy DeMario | Senior Director-Scientific & Data Analysis |
